Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04864795 · ClinicalTrials.gov registry record

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

A clinical trial, sponsored by Vifor (International).

Completed
Registry status
2,636
Enrollment target

NCT04864795 is a clinical trial that has completed, run by Vifor (International). The registered enrollment target is 2,636 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04864795 has completed, sponsored by Vifor (International).

COMPLETED
Registry status
2,636 participants
Enrollment target

Study Summary

The CARE-HK in HF is a registry study based on the hypothesis that adherence to guidelines is associated with improved real-world outcomes for heart failure (HF) patients. For the purpose of this study, adherence to guidelines is defined as adherence to RAASi treatment recommendations, according to the AHA/ACC and ESC guidelines. Objectives relating to patiromer effectiveness will only be evaluated if a sufficient number of patients are available. The study aims to evaluate in patients at high risk of hyperkalaemia; patients treated with ACEi/ARB/ARNi, and either treated with or candidates for treatment with MRA.

Trial Details

FieldValue
Enrollment Target 2,636 participants
Start Date 2021-04-19
Est. Completion 2024-08-30

Sponsor

Vifor (International)

2 total trials

What the Registry Record Tells You About NCT04864795

The ClinicalTrials.gov registry entry for NCT04864795 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor (International), which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04864795 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04864795 about?

NCT04864795 is a clinical study titled "Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia". The CARE-HK in HF is a registry study based on the hypothesis that adherence to guidelines is associated with improved real-world outcomes for heart failure (HF) patients. For the purpose of this study, adherence to guidelines is defined as adherence to RAASi treatment recommendations, according to ...

What is the current status of trial NCT04864795?

This trial is currently completed. The enrollment target is 2,636 participants. The study started on 2021-04-19. Estimated completion is 2024-08-30.

Who is sponsoring clinical trial NCT04864795?

This trial is sponsored by Vifor (International), which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.